Alopecia Areata: An Autoimmune Disease of Multiple Players

References

• Safavi K. Prevalence of alopecia areata in the first national health and nutrition examination survey. Arch Dermatol. 1992;128(5):702. doi:10.1001/archderm.1992.01680150136027
   PubMedGoogle Scholar
• Tan E, Tay YK, Goh CL, Chin Giam Y. The pattern and profile of alopecia areata in Singapore--a study of 219 Asians. Int J Dermatol. 2002;41(11):748–753. doi:10.1046/j.1365-4362.2002.01357.x
   PubMed Web of Science ®Google Scholar
• Cash TF. The psychology of hair loss and its implications for patient care. Clin Dermatol. 2001;19(2):161–166. doi:10.1016/S0738-081X(00)00127-9
   PubMed Web of Science ®Google Scholar
• Khunkhet S, Vachiramon V, Suchonwanit P. Trichoscopic clues for diagnosis of alopecia areata and trichotillomania in Asians. Int J Dermatol. 2017;56(2):161–165. doi:10.1111/ijd.13453
   PubMed Web of Science ®Google Scholar
• Leerunyakul K, Suchonwanit P. Asian hair: a review of structures, properties, and distinctive disorders. Clin Cosmet Investig Dermatol. 2020;13:309–318. doi:10.2147/CCID.S247390
   PubMed Web of Science ®Google Scholar
• Perret C, Wiesner-Menzel L, Happle R. Immunohistochemical analysis of T-cell subsets in the peribulbar and intrabulbar infiltrates of alopecia areata. Acta Derm Venereol. 1984;64(1):26–30.
   PubMed Web of Science ®Google Scholar
• Whiting DA. Histopathologic features of alopecia areata: a new look. Arch Dermatol. 2003;139(12):1555–1559. doi:10.1001/archderm.139.12.1555
   PubMed Web of Science ®Google Scholar
• Stefanato CM. Histopathology of alopecia: a clinicopathological approach to diagnosis. Histopathology. 2010;56(1):24–38. doi:10.1111/j.1365-2559.2009.03439.x
   PubMed Web of Science ®Google Scholar
• Suchonwanit P, Kositkuljorn C, Mahasaksiri T, Leerunyakul K. A comparison of the efficacy and tolerability of three corticosteroid treatment regimens in patients with alopecia areata. J Dermatolog Treat. 2020;1–6. doi:10.1080/09546634.2020.1773384
   Web of Science ®Google Scholar
• Ikeda T. Produced alopecia areata based on the focal infection theory and mental motive theory. Dermatologica. 1967;134(1):1–11. doi:10.1159/000254233
   PubMedGoogle Scholar
• Meephansan J, Thummakriengkrai J, Ponnikorn S, Yingmema W, Deenonpoe R, Suchonwanit P. Efficacy of topical tofacitinib in promoting hair growth in non-scarring alopecia: possible mechanism via VEGF induction. Arch Dermatol Res. 2017;309(9):729–738. doi:10.1007/s00403-017-1777-5
   PubMed Web of Science ®Google Scholar
• Chanasumon N, Sriphojanart T, Suchonwanit P. Therapeutic potential of bimatoprost for the treatment of eyebrow hypotrichosis. Drug Des Devel Ther. 2018;12:365–372. doi:10.2147/DDDT.S156467
   PubMed Web of Science ®Google Scholar
• Rojhirunsakool S, Suchonwanit P. Parietal scalp is another affected area in female pattern hair loss: an analysis of hair density and hair diameter. Clin Cosmet Investig Dermatol. 2018;11:7–12. doi:10.2147/CCID.S153768
   PubMed Web of Science ®Google Scholar
• Azzawi S, Penzi LR, Senna MM. Immune privilege collapse and alopecia development: is stress a factor. Skin Appendage Disord. 2018;4(4):236–244. doi:10.1159/000485080
   PubMed Web of Science ®Google Scholar
• Paus R, Ito N, Takigawa M, Ito T. The hair follicle and immune privilege. J Investig Dermatol Symp Proc. 2003;8(2):188–194. doi:10.1046/j.1087-0024.2003.00807.x
   PubMed Web of Science ®Google Scholar
• Barker CF, Billingham RE. Analysis of local anatomic factors that influence the survival times of pure epidermal and full-thickness skin homografts in guinea pigs. Ann Surg. 1972;176(5):597–604. doi:10.1097/00000658-197211000-00004
   Web of Science ®Google Scholar
• Harnchoowong S, Suchonwanit P. PPAR-γ agonists and their role in primary cicatricial alopecia. PPAR Res. 2017;2017:2501248. doi:10.1155/2017/2501248
   Web of Science ®Google Scholar
• Ito T, Ito N, Bettermann A, Tokura Y, Takigawa M, Paus R. Collapse and restoration of MHC class-I-dependent immune privilege: exploiting the human hair follicle as a model. Am J Pathol. 2004;164(2):623–634. doi:10.1016/S0002-9440(10)63151-3
   PubMed Web of Science ®Google Scholar
• Suchonwanit P, Hector CE, Bin Saif GA, McMichael AJ. Factors affecting the severity of central centrifugal cicatricial alopecia. Int J Dermatol. 2016;55(6):e338–343. doi:10.1111/ijd.13061
   PubMed Web of Science ®Google Scholar
• Brocker EB, Echternacht-Happle K, Hamm H, Happle R. Abnormal expression of class I and class II major histocompatibility antigens in alopecia areata: modulation by topical immunotherapy. J Invest Dermatol. 1987;88(5):564–568. doi:10.1111/1523-1747.ep12470166
   Web of Science ®Google Scholar
• Rosenblum MD, Yancey KB, Olasz EB, Truitt RL. CD200, a “no danger” signal for hair follicles. J Dermatol Sci. 2006;41(3):165–174. doi:10.1016/j.jdermsci.2005.11.003
   Web of Science ®Google Scholar
• Bertolini M, Meyer KC, Slominski R, Kobayashi K, Ludwig RJ, Paus R. The immune system of mouse vibrissae follicles: cellular composition and indications of immune privilege. Exp Dermatol. 2013;22(9):593–598. doi:10.1111/exd.12205
   Web of Science ®Google Scholar
• Ito T, Ito N, Saatoff M, et al. Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack. J Invest Dermatol. 2008;128(5):1196–1206. doi:10.1038/sj.jid.5701183
   PubMed Web of Science ®Google Scholar
• Gilhar A, Kalish RS. Alopecia areata: a tissue specific autoimmune disease of the hair follicle. Autoimmun Rev. 2006;5(1):64–69. doi:10.1016/j.autrev.2005.07.001
   PubMed Web of Science ®Google Scholar
• Subramanya RD, Coda AB, Sinha AA. Transcriptional profiling in alopecia areata defines immune and cell cycle control related genes within disease-specific signatures. Genomics. 2010;96(3):146–153. doi:10.1016/j.ygeno.2010.05.002
   PubMed Web of Science ®Google Scholar
• Kang H, Wu WY, Lo BK, et al. Hair follicles from alopecia areata patients exhibit alterations in immune privilege-associated gene expression in advance of hair loss. J Invest Dermatol. 2010;130(11):2677–2680. doi:10.1038/jid.2010.180
   PubMed Web of Science ®Google Scholar
• Bertolini M, Zilio F, Rossi A, et al. Abnormal interactions between perifollicular mast cells and CD8+ T-cells may contribute to the pathogenesis of alopecia areata. PLoS One. 2014;9(5):e94260. doi:10.1371/journal.pone.0094260
   PubMed Web of Science ®Google Scholar
• Ito T, Suzuki T, Sakabe JI, Funakoshi A, Fujiyama T, Tokura Y. Plasmacytoid dendritic cells as a possible key player to initiate alopecia areata in the C3H/HeJ mouse. Allergol Int. 2020;69(1):121–131. doi:10.1016/j.alit.2019.07.009
   Web of Science ®Google Scholar
• Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20(9):1043–1049. doi:10.1038/nm.3645
   PubMed Web of Science ®Google Scholar
• McElwee KJ, Boggess D, King LE Jr, Sundberg JP. Experimental induction of alopecia areata-like hair loss in C3H/HeJ mice using full-thickness skin grafts. J Invest Dermatol. 1998;111(5):797–803. doi:10.1046/j.1523-1747.1998.00380.x
   PubMed Web of Science ®Google Scholar
• Gilhar A, Krueger GG. Hair growth in scalp grafts from patients with alopecia areata and alopecia universalis grafted onto nude mice. Arch Dermatol. 1987;123(1):44–50. doi:10.1001/archderm.1987.01660250050016
   Google Scholar
• Gilhar A, Landau M, Assy B, Shalaginov R, Serafimovich S, Kalish RS. Melanocyte-associated T cell epitopes can function as autoantigens for transfer of alopecia areata to human scalp explants on Prkdc(scid) mice. J Invest Dermatol. 2001;117(6):1357–1362. doi:10.1046/j.0022-202x.2001.01583.x
   Web of Science ®Google Scholar
• Wang EHC, Yu M, Breitkopf T, et al. Identification of autoantigen epitopes in alopecia areata. J Invest Dermatol. 2016;136(8):1617–1626. doi:10.1016/j.jid.2016.04.004
   Web of Science ®Google Scholar
• Leung MC, Sutton CW, Fenton DA, Tobin DJ. Trichohyalin is a potential major autoantigen in human alopecia areata. J Proteome Res. 2010;9(10):5153–5163. doi:10.1021/pr100422u
   PubMed Web of Science ®Google Scholar
• Paus R, Slominski A, Czarnetzki BM. Is alopecia areata an autoimmune-response against melanogenesis-related proteins, exposed by abnormal MHC class I expression in the anagen hair bulb? Yale J Biol Med. 1993;66(6):541–554.
   PubMed Web of Science ®Google Scholar
• Chanprapaph K, Udompanich S, Visessiri Y, Ngamjanyaporn P, Suchonwanit P. Nonscarring alopecia in systemic lupus erythematosus: a cross-sectional study with trichoscopic, histopathologic, and immunopathologic analyses. J Am Acad Dermatol. 2019;81(6):1319–1329. doi:10.1016/j.jaad.2019.05.053
   PubMed Web of Science ®Google Scholar
• Suchonwanit P, Udompanich S, Thadanipon K, Chanprapaph K. Trichoscopic signs in systemic lupus erythematosus: a comparative study with 109 patients and 305 healthy controls. J Eur Acad Dermatol Venereol. 2019;33(4):774–780. doi:10.1111/jdv.15421
   PubMed Web of Science ®Google Scholar
• Pratt CH, King LE Jr, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primers. 2017;3:17011. doi:10.1038/nrdp.2017.11
   PubMed Web of Science ®Google Scholar
• Gilhar A, Etzioni A, Paus R. Alopecia areata. N Engl J Med. 2012;366(16):1515–1525. doi:10.1056/NEJMra1103442
   PubMed Web of Science ®Google Scholar
• de Jong A, Jabbari A, Dai Z, et al. High-throughput T cell receptor sequencing identifies clonally expanded CD8+ T cell populations in alopecia areata. JCI Insight. 2018;3(19). doi:10.1172/jci.insight.121949.
   PubMed Web of Science ®Google Scholar
• McElwee KJ, Freyschmidt-Paul P, Hoffmann R, et al. Transfer of CD8(+) cells induces localized hair loss whereas CD4(+)/CD25(-) cells promote systemic alopecia areata and CD4(+)/CD25(+) cells blockade disease onset in the C3H/HeJ mouse model. J Invest Dermatol. 2005;124(5):947–957. doi:10.1111/j.0022-202X.2005.23692.x
   PubMed Web of Science ®Google Scholar
• Gilhar A, Keren A, Shemer A, d’Ovidio R, Ullmann Y, Paus R. Autoimmune disease induction in a healthy human organ: a humanized mouse model of alopecia areata. J Invest Dermatol. 2013;133(3):844–847. doi:10.1038/jid.2012.365
   Web of Science ®Google Scholar
• Ebrahim AA, Salem RM, El Fallah AA, Younis ET. Serum Interleukin-15 is a Marker of Alopecia Areata Severity. Int J Trichology. 2019;11(1):26–30. doi:10.4103/ijt.ijt_80_18
   Google Scholar
• Fuentes-Duculan J, Gulati N, Bonifacio KM, et al. Biomarkers of alopecia areata disease activity and response to corticosteroid treatment. Exp Dermatol. 2016;25(4):282–286. doi:10.1111/exd.12918
   Web of Science ®Google Scholar
• Ghoreishi M, Martinka M, Dutz JP. Type 1 interferon signature in the scalp lesions of alopecia areata. Br J Dermatol. 2010;163(1):57–62. doi:10.1111/j.1365-2133.2010.09775.x
   PubMed Web of Science ®Google Scholar
• McPhee CG, Duncan FJ, Silva KA, et al. Increased expression of Cxcr3 and its ligands, Cxcl9 and Cxcl10, during the development of alopecia areata in the mouse. J Invest Dermatol. 2012;132(6):1736–1738. doi:10.1038/jid.2012.17
   Web of Science ®Google Scholar
• Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol. 2015;8:397–403.
   PubMed Web of Science ®Google Scholar
• Tanemura A, Oiso N, Nakano M, Itoi S, Kawada A, Katayama I. Alopecia areata: infiltration of Th17 cells in the dermis, particularly around hair follicles. Dermatology. 2013;226(4):333–336. doi:10.1159/000350933
   PubMed Web of Science ®Google Scholar
• Lee GR. The balance of Th17 versus treg cells in autoimmunity. Int J Mol Sci. 2018;19(3):730.
   PubMed Web of Science ®Google Scholar
• Othy S, Jairaman A, Dynes JL, et al. Regulatory T cells suppress Th17 cell Ca(2+) signaling in the spinal cord during murine autoimmune neuroinflammation. Proc Natl Acad Sci U S A. 2020;117(33):20088–20099. doi:10.1073/pnas.2006895117
   Web of Science ®Google Scholar
• Loh SH, Moon HN, Lew BL, Sim WY. Role of T helper 17 cells and T regulatory cells in alopecia areata: comparison of lesion and serum cytokine between controls and patients. J Eur Acad Dermatol Venereol. 2018;32(6):1028–1033. doi:10.1111/jdv.14775
   Web of Science ®Google Scholar
• Ghoreschi K, Laurence A, Yang XP, Hirahara K, O’Shea JJ. T helper 17 cell heterogeneity and pathogenicity in autoimmune disease. Trends Immunol. 2011;32(9):395–401. doi:10.1016/j.it.2011.06.007
   PubMed Web of Science ®Google Scholar
• Noack M, Miossec P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev. 2014;13(6):668–677. doi:10.1016/j.autrev.2013.12.004
   PubMed Web of Science ®Google Scholar
• Han YM, Sheng YY, Xu F, et al. Imbalance of T-helper 17 and regulatory T cells in patients with alopecia areata. J Dermatol. 2015;42(10):981–988. doi:10.1111/1346-8138.12978
   PubMed Web of Science ®Google Scholar
• Abou Rahal J, Kurban M, Kibbi AG, Abbas O. Plasmacytoid dendritic cells in alopecia areata: missing link? J Eur Acad Dermatol Venereol. 2016;30(1):119–123. doi:10.1111/jdv.12932
   PubMed Web of Science ®Google Scholar
• Saadeh D, Kurban M, Abbas O. Update on the role of plasmacytoid dendritic cells in inflammatory/autoimmune skin diseases. Exp Dermatol. 2016;25(6):415–421. doi:10.1111/exd.12957
   PubMed Web of Science ®Google Scholar
• McKenna K, Beignon AS, Bhardwaj N. Plasmacytoid dendritic cells: linking innate and adaptive immunity. J Virol. 2005;79(1):17–27. doi:10.1128/JVI.79.1.17-27.2005
   PubMed Web of Science ®Google Scholar
• Paus R, Bulfone-Paus S, Bertolini M. Hair follicle immune privilege revisited: the key to alopecia areata management. J Investig Dermatol Symp Proc. 2018;19(1):S12–S17. doi:10.1016/j.jisp.2017.10.014
   PubMedGoogle Scholar
• Sundberg JP, Boggess D, Montagutelli X, Hogan ME, King LE Jr. C3H/HeJ mouse model for alopecia areata. J Invest Dermatol. 1995;104(5 Suppl):16S–17S. doi:10.1038/jid.1995.38
   Google Scholar
• Freyschmidt-Paul P, McElwee KJ, Hoffmann R, et al. Interferon-gamma-deficient mice are resistant to the development of alopecia areata. Br J Dermatol. 2006;155(3):515–521. doi:10.1111/j.1365-2133.2006.07377.x
   PubMed Web of Science ®Google Scholar
• Nakamura M, Jo J, Tabata Y, Ishikawa O. Controlled delivery of T-box21 small interfering RNA ameliorates autoimmune alopecia (Alopecia Areata) in a C3H/HeJ mouse model. Am J Pathol. 2008;172(3):650–658. doi:10.2353/ajpath.2008.061249
   Web of Science ®Google Scholar
• Arca E, Musabak U, Akar A, Erbil AH, Tastan HB. Interferon-gamma in alopecia areata. Eur J Dermatol. 2004;14(1):33–36.
   PubMed Web of Science ®Google Scholar
• Triyangkulsri K, Suchonwanit P. Role of janus kinase inhibitors in the treatment of alopecia areata. Drug Des Devel Ther. 2018;12:2323–2335. doi:10.2147/DDDT.S172638
   PubMed Web of Science ®Google Scholar
• Thein C, Strange P, Hansen ER, Baadsgaard O. Lesional alopecia areata T lymphocytes downregulate epithelial cell proliferation. Arch Dermatol Res. 1997;289(7):384–388. doi:10.1007/s004030050209
   Web of Science ®Google Scholar
• Kasumagic-Halilovic E, Prohic A, Cavaljuga S. Tumor necrosis factor-alpha in patients with alopecia areata. Indian J Dermatol. 2011;56(5):494–496. doi:10.4103/0019-5154.87124
   PubMedGoogle Scholar
• Hoffmann R, Eicheler W, Huth A, Wenzel E, Happle R. Cytokines and growth factors influence hair growth in vitro. Possible implications for the pathogenesis and treatment of alopecia areata. Arch Dermatol Res. 1996;288(3):153–156. doi:10.1007/BF02505825
   PubMed Web of Science ®Google Scholar
• Kollias G, Kontoyiannis D. Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments. Cytokine Growth Factor Rev. 2002;13(4–5):315–321. doi:10.1016/S1359-6101(02)00019-9
   PubMed Web of Science ®Google Scholar
• Galbraith GM, Pandey JP. Tumor necrosis factor alpha (TNF-alpha) gene polymorphism in alopecia areata. Hum Genet. 1995;96(4):433–436. doi:10.1007/BF00191802
   Web of Science ®Google Scholar
• Suchonwanit P, Chalermroj N, Khunkhet S. Low-level laser therapy for the treatment of androgenetic alopecia in Thai men and women: a 24-week, randomized, double-blind, sham device-controlled trial. Lasers Med Sci. 2019;34(6):1107–1114. doi:10.1007/s10103-018-02699-9
   PubMed Web of Science ®Google Scholar
• Paus R, Nickoloff BJ, Ito T. A ‘hairy’ privilege. Trends Immunol. 2005;26(1):32–40. doi:10.1016/j.it.2004.09.014
   PubMed Web of Science ®Google Scholar
• Groom JR, Luster AD. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol. 2011;89(2):207–215. doi:10.1038/icb.2010.158
   PubMed Web of Science ®Google Scholar
• Rotondi M, Chiovato L, Romagnani S, Serio M, Romagnani P. Role of chemokines in endocrine autoimmune diseases. Endocr Rev. 2007;28(5):492–520. doi:10.1210/er.2006-0044
   PubMed Web of Science ®Google Scholar
• Dai Z, Xing L, Cerise J, et al. CXCR3 blockade inhibits T cell migration into the skin and prevents development of alopecia areata. J Immunol. 2016;197(4):1089–1099. doi:10.4049/jimmunol.1501798
   Web of Science ®Google Scholar
• Suarez-Farinas M, Ungar B, Noda S, et al. Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewing. J Allergy Clin Immunol. 2015;136(5):1277–1287. doi:10.1016/j.jaci.2015.06.032
   PubMed Web of Science ®Google Scholar
• McElwee KJ, Hoffmann R. Alopecia areata - animal models. Clin Exp Dermatol. 2002;27(5):410–417. doi:10.1046/j.1365-2230.2002.01075.x
   PubMed Web of Science ®Google Scholar
• Chu SY, Chen YJ, Tseng WC, et al. Comorbidity profiles among patients with alopecia areata: the importance of onset age, a nationwide population-based study. J Am Acad Dermatol. 2011;65(5):949–956. doi:10.1016/j.jaad.2010.08.032
   PubMed Web of Science ®Google Scholar
• Attia EA, El Shennawy D, Sefin A. Serum interleukin-4 and total immunoglobulin E in nonatopic alopecia areata patients and HLA-DRB1 typing. Dermatol Res Pract. 2010;2010:503587. doi:10.1155/2010/503587
   Google Scholar
• Song T, Pavel AB, Wen HC, et al. An integrated model of alopecia areata biomarkers highlights both TH1 and TH2 upregulation. J Allergy Clin Immunol. 2018;142(5):1631–1634 e1613. doi:10.1016/j.jaci.2018.06.029
   PubMed Web of Science ®Google Scholar
• Inui S, Noguchi F, Nakajima T, Itami S. Serum thymus and activation-regulated chemokine as disease activity and response biomarker in alopecia areata. J Dermatol. 2013;40(11):881–885. doi:10.1111/1346-8138.12273
   Web of Science ®Google Scholar
• Kanokrungsee S, Anuntrangsee T, Tankunakorn J, Srisuwanwattana P, Suchonwanit P, Chanprapaph K. Rituximab therapy for treatment of pemphigus in Southeast Asians. Drug Des Devel Ther. 2021;15:1677–1690. doi:10.2147/DDDT.S306046
   Web of Science ®Google Scholar
• Muller SA, Winkelmann RK. Alopecia areata. an evaluation of 736 patients. Arch Dermatol. 1963;88:290–297. doi:10.1001/archderm.1963.01590210048007
   PubMed Web of Science ®Google Scholar
• Shellow WV, Edwards JE, Koo JY. Profile of alopecia areata: a questionnaire analysis of patient and family. Int J Dermatol. 1992;31(3):186–189. doi:10.1111/j.1365-4362.1992.tb03932.x
   PubMed Web of Science ®Google Scholar
• Suchonwanit P, Triamchaisri S, Wittayakornrerk S, Rattanakaemakorn P. Leprosy reaction in thai population: a 20-year retrospective study. Dermatol Res Pract. 2015;2015:253154. doi:10.1155/2015/253154
   PubMedGoogle Scholar
• Boonsakan P, Iamsumang W, Chantrathammachart P, Chayavichitsilp P, Suchonwanit P, Rutnin S. Prognostic value of concurrent expression of C-MYC and BCL2 in intravascular large B-cell lymphoma: a 10-year retrospective study. Biomed Res Int. 2020;2020:1350820. doi:10.1155/2020/1350820
   Web of Science ®Google Scholar
• Blaumeiser B, van der Goot I, Fimmers R, et al. Familial aggregation of alopecia areata. J Am Acad Dermatol. 2006;54(4):627–632. doi:10.1016/j.jaad.2005.12.007
   PubMed Web of Science ®Google Scholar
• Jackow C, Puffer N, Hordinsky M, Nelson J, Tarrand J, Duvic M. Alopecia areata and cytomegalovirus infection in twins: genes versus environment? J Am Acad Dermatol. 1998;38(3):418–425. doi:10.1016/S0190-9622(98)70499-2
   PubMed Web of Science ®Google Scholar
• Rodriguez TA, Fernandes KE, Dresser KL, Duvic M; National Alopecia Areata R. Concordance rate of alopecia areata in identical twins supports both genetic and environmental factors. J Am Acad Dermatol. 2010;62(3):525–527. doi:10.1016/j.jaad.2009.02.006
   PubMed Web of Science ®Google Scholar
• Kungvalpivat P, Rojhirunsakool S, Chayavichitsilp P, Suchonwanit P, Wichayachakorn CT, Rutnin S. Clinical and onychoscopic features of benign and malignant conditions in longitudinal melanonychia in the thai population: a comparative analysis. Clin Cosmet Investig Dermatol. 2020;13:857–865. doi:10.2147/CCID.S283112
   Web of Science ®Google Scholar
• Colombe BW, Price VH, Khoury EL, Garovoy MR, Lou CD. HLA class II antigen associations help to define two types of alopecia areata. J Am Acad Dermatol. 1995;33(5 Pt 1):757–764.
   PubMed Web of Science ®Google Scholar
• Sundberg JP, Silva KA, Li R, Cox GA, King LE. Adult-onset Alopecia areata is a complex polygenic trait in the C3H/HeJ mouse model. J Invest Dermatol. 2004;123(2):294–297. doi:10.1111/j.0022-202X.2004.23222.x
   PubMed Web of Science ®Google Scholar
• Barahmani N, de Andrade M, Slusser JP, Zhang Q, Duvic M. Major histocompatibility complex class I chain-related gene A polymorphisms and extended haplotypes are associated with familial alopecia areata. J Invest Dermatol. 2006;126(1):74–78. doi:10.1038/sj.jid.5700009
   Web of Science ®Google Scholar
• Petukhova L, Duvic M, Hordinsky M, et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature. 2010;466(7302):113–117. doi:10.1038/nature09114
   PubMed Web of Science ®Google Scholar
• Jagielska D, Redler S, Brockschmidt FF, et al. Follow-up study of the first genome-wide association scan in alopecia areata: IL13 and KIAA0350 as susceptibility loci supported with genome-wide significance. J Invest Dermatol. 2012;132(9):2192–2197. doi:10.1038/jid.2012.129
   PubMed Web of Science ®Google Scholar
• Kemp EH, McDonagh AJ, Wengraf DA, et al. The non-synonymous C1858T substitution in the PTPN22 gene is associated with susceptibility to the severe forms of alopecia areata. Hum Immunol. 2006;67(7):535–539. doi:10.1016/j.humimm.2006.04.006
   PubMed Web of Science ®Google Scholar
• Arck PC, Handjiski B, Peters EM, et al. Stress inhibits hair growth in mice by induction of premature catagen development and deleterious perifollicular inflammatory events via neuropeptide substance P-dependent pathways. Am J Pathol. 2003;162(3):803–814. doi:10.1016/S0002-9440(10)63877-1
   PubMed Web of Science ®Google Scholar
• Chanprapaph K, Sutharaphan T, Suchonwanit P. Scalp biophysical characteristics in males with androgenetic alopecia: a comparative study with healthy controls. Clin Interv Aging. 2021;16:781–787. doi:10.2147/CIA.S310178
   PubMed Web of Science ®Google Scholar
• Peters EM, Handjiski B, Kuhlmei A, et al. Neurogenic inflammation in stress-induced termination of murine hair growth is promoted by nerve growth factor. Am J Pathol. 2004;165(1):259–271. doi:10.1016/S0002-9440(10)63294-4
   Web of Science ®Google Scholar
• Theoharides TC, Donelan JM, Papadopoulou N, Cao J, Kempuraj D, Conti P. Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol Sci. 2004;25(11):563–568. doi:10.1016/j.tips.2004.09.007
   PubMed Web of Science ®Google Scholar
• Suchonwanit P, Iamsumang W, Rojhirunsakool S. Efficacy of topical combination of 0.25% finasteride and 3% minoxidil versus 3% minoxidil solution in female pattern hair loss: a randomized, double-blind, controlled study. Am J Clin Dermatol. 2019;20(1):147–153. doi:10.1007/s40257-018-0387-0
   PubMed Web of Science ®Google Scholar
• Suchonwanit P, Srisuwanwattana P, Chalermroj N, Khunkhet S. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia. J Eur Acad Dermatol Venereol. 2018;32(12):2257–2263. doi:10.1111/jdv.15171
   PubMed Web of Science ®Google Scholar
• Suchonwanit P, Rojhirunsakool S, Khunkhet S. A randomized, investigator-blinded, controlled, split-scalp study of the efficacy and safety of a 1550-nm fractional erbium-glass laser, used in combination with topical 5% minoxidil versus 5% minoxidil alone, for the treatment of androgenetic alopecia. Lasers Med Sci. 2019;34(9):1857–1864. doi:10.1007/s10103-019-02783-8
   PubMed Web of Science ®Google Scholar
• Skinner RB Jr, Light WH, Bale GF, Rosenberg EW, Leonardi C. Alopecia areata and presence of cytomegalovirus DNA. JAMA. 1995;273(18):1419–1420. doi:10.1001/jama.1995.03520420031025
   PubMed Web of Science ®Google Scholar
• Tosti A, La Placa M, Placucci F, et al. No correlation between cytomegalovirus and alopecia areata. J Invest Dermatol. 1996;107(3):443. doi:10.1111/1523-1747.ep12365508
   Web of Science ®Google Scholar
• Rodriguez TA, Duvic M; National Alopecia Areata R. Onset of alopecia areata after Epstein-Barr virus infectious mononucleosis. J Am Acad Dermatol. 2008;59(1):137–139. doi:10.1016/j.jaad.2008.02.005
   PubMed Web of Science ®Google Scholar
• Ito T, Tokura Y. Alopecia areata triggered or exacerbated by swine flu virus infection. J Dermatol. 2012;39(10):863–864. doi:10.1111/j.1346-8138.2011.01437.x
   PubMed Web of Science ®Google Scholar
• Jin W, Zheng H, Shan B, Wu Y. Changes of serum trace elements level in patients with alopecia areata: a meta-analysis. J Dermatol. 2017;44(5):588–591. doi:10.1111/1346-8138.13705
   Web of Science ®Google Scholar
• Abdel Fattah NS, Atef MM, Al-Qaradaghi SM. Evaluation of serum zinc level in patients with newly diagnosed and resistant alopecia areata. Int J Dermatol. 2016;55(1):24–29. doi:10.1111/ijd.12769
   Web of Science ®Google Scholar
• Wise RP, Kiminyo KP, Salive ME. Hair loss after routine immunizations. JAMA. 1997;278(14):1176–1178. doi:10.1001/jama.1997.03550140068042
   PubMed Web of Science ®Google Scholar
• Sundberg JP, Silva KA, Zhang W, et al. Recombinant human hepatitis B vaccine initiating alopecia areata: testing the hypothesis using the C3H/HeJ mouse model. Vet Dermatol. 2009;20(2):99–104. doi:10.1111/j.1365-3164.2008.00692.x
   Web of Science ®Google Scholar
• Huang KP, Mullangi S, Guo Y, Qureshi AA. Autoimmune, atopic, and mental health comorbid conditions associated with alopecia areata in the United States. JAMA Dermatol. 2013;149(7):789–794. doi:10.1001/jamadermatol.2013.3049
   PubMed Web of Science ®Google Scholar
• Magen E, Chikovani T, Waitman DA, Kahan NR. Association of alopecia areata with atopic dermatitis and chronic spontaneous urticaria. Allergy Asthma Proc. 2018;39(2):96–102. doi:10.2500/aap.2018.39.4114
   Web of Science ®Google Scholar
• Li SF, Zhang XT, Qi SL, et al. Allergy to dust mites may contribute to early onset and severity of alopecia areata. Clin Exp Dermatol. 2015;40(2):171–176. doi:10.1111/ced.12471
   Web of Science ®Google Scholar
• Shapiro J. Current treatment of alopecia areata. J Investig Dermatol Symp Proc. 2013;16(1):S42–44. doi:10.1038/jidsymp.2013.14
   PubMedGoogle Scholar
• Rattananukrom T, Suchonwanit P. Are drug treatment strategies really effective against alopecia areata? Expert Opin Pharmacother. 2021;22(3):257–260. doi:10.1080/14656566.2020.1854728
   PubMed Web of Science ®Google Scholar
• Zoller M, McElwee KJ, Vitacolonna M, Hoffmann R. The progressive state, in contrast to the stable or regressive state of alopecia areata, is reflected in peripheral blood mononuclear cells. Exp Dermatol. 2004;13(7):435–444. doi:10.1111/j.0906-6705.2004.00179.x
   PubMed Web of Science ®Google Scholar
• Manimaran RP, Ramassamy S, Rajappa M, Chandrashekar L. Therapeutic outcome of diphencyprone and its correlation with serum cytokine profile in alopecia areata. J Dermatolog Treat. 2020;1–5. doi:10.1080/09546634.2020.1752887
   Web of Science ®Google Scholar
• Kuwano Y, Fujimoto M, Watanabe R, et al. Serum chemokine profiles in patients with alopecia areata. Br J Dermatol. 2007;157(3):466–473. doi:10.1111/j.1365-2133.2007.07943.x
   Web of Science ®Google Scholar
• Konig A, Happle R, Hoffmann R. IFN-gamma-induced HLA-DR but not ICAM-1 expression on cultured dermal papilla cells is downregulated by TNF-alpha. Arch Dermatol Res. 1997;289(8):466–470. doi:10.1007/s004030050222
   PubMed Web of Science ®Google Scholar
• Happle R, Hausen BM, Wiesner-Menzel L. Diphencyprone in the treatment of alopecia areata. Acta Derm Venereol. 1983;63(1):49–52.
   PubMed Web of Science ®Google Scholar
• Messenger AG, McKillop J, Farrant P, McDonagh AJ, Sladden M. British Association of Dermatologists’ guidelines for the management of alopecia areata 2012. Br J Dermatol. 2012;166(5):916–926. doi:10.1111/j.1365-2133.2012.10955.x
   PubMed Web of Science ®Google Scholar
• Mahasaksiri T, Kositkuljorn C, Anuntrangsee T, Suchonwanit P. Application of topical immunotherapy in the treatment of alopecia areata: a review and update. Drug Des Devel Ther. 2021;15:1285–1298. doi:10.2147/DDDT.S297858
   PubMed Web of Science ®Google Scholar
• Durdu M, Ozcan D, Baba M, Seckin D. Efficacy and safety of diphenylcyclopropenone alone or in combination with anthralin in the treatment of chronic extensive alopecia areata: a retrospective case series. J Am Acad Dermatol. 2015;72(4):640–650. doi:10.1016/j.jaad.2015.01.008
   PubMed Web of Science ®Google Scholar
• Ibrahim SA, Esawy AM, Abdelshafy AS. Treatment of chronic extensive alopecia areata by diphenylcyclopropenone alone versus in combination with anthralin. Dermatol Ther. 2019;32(5):e13010. doi:10.1111/dth.13010
   Web of Science ®Google Scholar
• Kagami S, Kishi Y, Hino H. Topical immunotherapy in combination with anthralin in the treatment of refractory alopecia areata. J Cosmet Dermatol. 2020;19(9):2411–2414. doi:10.1111/jocd.13588
   Web of Science ®Google Scholar
• Nasimi M, Ghandi N, Abedini R, Mirshamsi A, Shakoei S, Seirafi H. Efficacy and safety of anthralin in combination with diphenylcyclopropenone in the treatment of alopecia areata: a retrospective case series. Arch Dermatol Res. 2019;311(8):607–613. doi:10.1007/s00403-019-01940-x
   Web of Science ®Google Scholar
• Shapiro J, Tan J, Ho V, Abbott F, Tron V. Treatment of chronic severe alopecia areata with topical diphenylcyclopropenone and 5% minoxidil: a clinical and immunopathologic evaluation. J Am Acad Dermatol. 1993;29(5 Pt 1):729–735. doi:10.1016/0190-9622(93)70238-O
   Web of Science ®Google Scholar
• Wasylyszyn T, Borowska K. Possible advantage of imiquimod and diphenylcyclopropenone combined treatment versus diphenylcyclopropenone alone: an observational study of nonresponder patients with alopecia areata. Australas J Dermatol. 2017;58(3):219–223. doi:10.1111/ajd.12478
   Web of Science ®Google Scholar
• Sriphojanart T, Khunkhet S, Suchonwanit P. A retrospective comparative study of the efficacy and safety of two regimens of diphenylcyclopropenone in the treatment of recalcitrant alopecia areata. Dermatol Rep. 2017;9(2):7399. doi:10.4081/dr.2017.7399
   PubMed Web of Science ®Google Scholar
• Thuangtong R, Varothai S, Triwongwaranat D, Rujitharanawong C. Multi-concentration level patch test guided diphenyl cyclopropenone (DPCP) treatment in alopecia totalis or alopecia universalis. J Med Assoc Thai. 2017;100(1):86–92.
   Google Scholar
• Lee S, Lee WS. Home-based contact immunotherapy with diphenylcyclopropenone for alopecia areata is as effective and safe as clinic-based treatment in patients with stable disease: a retrospective study of 40 patients. J Am Acad Dermatol. 2018;78(3):599–601.e591. doi:10.1016/j.jaad.2017.09.037
   Web of Science ®Google Scholar
• Nowicka D, Maj J, Jankowska-Konsur A, Hryncewicz-Gwozdz A. Efficacy of diphenylcyclopropenone in alopecia areata: a comparison of two treatment regimens. Postepy Dermatol Alergol. 2018;35(6):577–581. doi:10.5114/ada.2018.77608
   Web of Science ®Google Scholar
• Kim BJ, Lee S, Lee CH, Lee WS. Home-based contact immunotherapy with diphenylcyclopropenone improves compliance with the recommended follow-up for patients with alopecia areata: a retrospective cohort study. J Am Acad Dermatol. 2020;82(5):1223–1225. doi:10.1016/j.jaad.2019.10.043
   Web of Science ®Google Scholar
• Leonard WJ, O’Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol. 1998;16:293–322. doi:10.1146/annurev.immunol.16.1.293
   PubMed Web of Science ®Google Scholar
• Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O’Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;17(1):78. doi:10.1038/nrd.2017.267
   PubMed Web of Science ®Google Scholar
• Harel S, Higgins CA, Cerise JE, et al. Pharmacologic inhibition of JAK-STAT signaling promotes hair growth. Sci Adv. 2015;1(9):e1500973. doi:10.1126/sciadv.1500973
   PubMed Web of Science ®Google Scholar
• Rajabi F, Drake LA, Senna MM, Rezaei N. Alopecia areata: a review of disease pathogenesis. Br J Dermatol. 2018;179(5):1033–1048.
   PubMed Web of Science ®Google Scholar
• Forero-Pena DA, Gutierrez FR. Statins as modulators of regulatory T-cell biology. Mediators Inflamm. 2013;2013:167086. doi:10.1155/2013/167086
   PubMed Web of Science ®Google Scholar
• Cervantes J, Jimenez JJ, DelCanto GM, Tosti A. Treatment of alopecia areata with simvastatin/ezetimibe. J Investig Dermatol Symp Proc. 2018;19(1):S25–S31. doi:10.1016/j.jisp.2017.10.013
   PubMedGoogle Scholar
• Choi JW, Suh DW, Lew BL, Sim WY. Simvastatin/ezetimibe therapy for recalcitrant alopecia areata: an open prospective study of 14 patients. Ann Dermatol. 2017;29(6):755–760. doi:10.5021/ad.2017.29.6.755
   Web of Science ®Google Scholar
• Loi C, Starace M, Piraccini BM. Alopecia areata (AA) and treatment with simvastatin/ezetimibe: experience of 20 patients. J Am Acad Dermatol. 2016;74(5):e99–e100. doi:10.1016/j.jaad.2015.09.071
   Web of Science ®Google Scholar
• Lattouf C, Jimenez JJ, Tosti A, et al. Treatment of alopecia areata with simvastatin/ezetimibe. J Am Acad Dermatol. 2015;72(2):359–361. doi:10.1016/j.jaad.2014.11.006
   PubMed Web of Science ®Google Scholar
• Poole RM, Ballantyne AD. Apremilast: first global approval. Drugs. 2014;74(7):825–837. doi:10.1007/s40265-014-0218-4
   PubMed Web of Science ®Google Scholar
• Keren A, Shemer A, Ullmann Y, Paus R, Gilhar A. The PDE4 inhibitor, apremilast, suppresses experimentally induced alopecia areata in human skin in vivo. J Dermatol Sci. 2015;77(1):74–76. doi:10.1016/j.jdermsci.2014.11.009
   Web of Science ®Google Scholar
• Mikhaylov D, Pavel A, Yao C, et al. A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata. Arch Dermatol Res. 2019;311(1):29–36. doi:10.1007/s00403-018-1876-y
   PubMed Web of Science ®Google Scholar
• Liu LY, King BA. Lack of efficacy of apremilast in 9 patients with severe alopecia areata. J Am Acad Dermatol. 2017;77(4):773–774. doi:10.1016/j.jaad.2017.05.034
   PubMed Web of Science ®Google Scholar
• Zorn E, Nelson EA, Mohseni M, et al. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood. 2006;108(5):1571–1579. doi:10.1182/blood-2006-02-004747
   PubMed Web of Science ®Google Scholar
• Castela E, Le Duff F, Butori C, et al. Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata. JAMA Dermatol. 2014;150(7):748–751. doi:10.1001/jamadermatol.2014.504
   PubMed Web of Science ®Google Scholar
• Hordinsky M, Kaplan DH. Low-dose interleukin 2 to reverse alopecia areata. JAMA Dermatol. 2014;150(7):696–697. doi:10.1001/jamadermatol.2014.510
   Web of Science ®Google Scholar
• Skurkovich S, Korotky NG, Sharova NM, Skurkovich B. Treatment of alopecia areata with anti-interferon-gamma antibodies. J Investig Dermatol Symp Proc. 2005;10(3):283–284. doi:10.1111/j.0022-202X.2005.10130_6.x
   PubMedGoogle Scholar
• Strober BE, Siu K, Alexis AF, et al. Etanercept does not effectively treat moderate to severe alopecia areata: an open-label study. J Am Acad Dermatol. 2005;52(6):1082–1084. doi:10.1016/j.jaad.2005.03.039
   PubMed Web of Science ®Google Scholar
• Abramovits W, Losornio M. Failure of two TNF-alpha blockers to influence the course of alopecia areata. Skinmed. 2006;5(4):177–181. doi:10.1111/j.1540-9740.2006.05443.x
   PubMedGoogle Scholar
• Exarchou SA, Voulgari PV, Markatseli TE, Zioga A, Drosos AA. Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors. Scand J Rheumatol. 2009;38(5):328–331. doi:10.1080/03009740902922612
   PubMed Web of Science ®Google Scholar
• Slowinska M, Kardynal A, Warszawik O, Czuwara J, Rudnicka L. Alopecia areata developing paralell to improvement of psoriasis during ustekinumab therapy. J Dermatol Case Rep. 2010;4(1):15–17. doi:10.3315/jdcr.2010.1041
   Google Scholar
• Guttman-Yassky E, Ungar B, Noda S, et al. Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonism. J Allergy Clin Immunol. 2016;137(1):301–304. doi:10.1016/j.jaci.2015.11.001
   Web of Science ®Google Scholar
• Aleisa A, Lim Y, Gordon S, et al. Response to ustekinumab in three pediatric patients with alopecia areata. Pediatr Dermatol. 2019;36(1):e44–e45. doi:10.1111/pde.13699
   Web of Science ®Google Scholar
• Verros C, Rallis E, Crowe M. Letter: alopecia areata during ustekinumab administration: co-existence or an adverse reaction? Dermatol Online J. 2012;18(7):14. doi:10.5070/D34G31C0TM
   PubMedGoogle Scholar
• Strober BE, Menon K. Alefacept for the treatment of psoriasis and other dermatologic diseases. Dermatol Ther. 2007;20(4):270–276. doi:10.1111/j.1529-8019.2007.00140.x
   PubMed Web of Science ®Google Scholar
• Bui K, Polisetty S, Gilchrist H, Jackson SM, Frederic J. Successful treatment of alopecia universalis with alefacept: a case report and review of the literature. Cutis. 2008;81(5):431–434.
   PubMed Web of Science ®Google Scholar
• Strober BE, Menon K, McMichael A, et al. Alefacept for severe alopecia areata: a randomized, double-blind, placebo-controlled study. Arch Dermatol. 2009;145(11):1262–1266. doi:10.1001/archdermatol.2009.264
   PubMedGoogle Scholar
• Kaelin U, Hassan AS, Braathen LR, Yawalkar N. Treatment of alopecia areata partim universalis with efalizumab. J Am Acad Dermatol. 2006;55(3):529–532. doi:10.1016/j.jaad.2006.05.062
   Web of Science ®Google Scholar
• Smith JR, Akin RS, Wells MJ. Alopecia areata treated with efalizumab: a case with significant hair re-growth after long-term therapy. J Drugs Dermatol. 2009;8(8):758–760.
   Web of Science ®Google Scholar
• Price VH, Hordinsky MK, Olsen EA, et al. Subcutaneous efalizumab is not effective in the treatment of alopecia areata. J Am Acad Dermatol. 2008;58(3):395–402. doi:10.1016/j.jaad.2007.10.645
   Web of Science ®Google Scholar
• Udompanich S, Chanprapaph K, Suchonwanit P. Hair and scalp changes in cutaneous and systemic lupus erythematosus. Am J Clin Dermatol. 2018;19(5):679–694. doi:10.1007/s40257-018-0363-8
   PubMed Web of Science ®Google Scholar
• Iamsumang W, Leerunyakul K, Suchonwanit P. Finasteride and its potential for the treatment of female pattern hair loss: evidence to date. Drug Des Devel Ther. 2020;14:951–959. doi:10.2147/DDDT.S240615
   PubMed Web of Science ®Google Scholar
• Leerunyakul K, Suchonwanit P. Evaluation of hair density and hair diameter in the adult thai population using quantitative trichoscopic analysis. Biomed Res Int. 2020;2020:2476890. doi:10.1155/2020/2476890
   PubMed Web of Science ®Google Scholar
• Suchonwanit P, McMichael AJ. Alopecia in association with malignancy: a review. Am J Clin Dermatol. 2018;19(6):853–865. doi:10.1007/s40257-018-0378-1
   PubMed Web of Science ®Google Scholar
• Rattanakaemakorn P, Triyangkulsri K, Iamsumang W, Suchonwanit P. 308-nm excimer lamp vs. Combination of 308-nm excimer lamp and 10% liquor carbonis detergens in patients with scalp psoriasis: a randomized, single-blinded, controlled trial. Front Med (Lausanne). 2021;8:677948. doi:10.3389/fmed.2021.677948
   Web of Science ®Google Scholar
• Chanprapaph K, Fakprapai W, Limtong P, Suchonwanit P. Nailfold capillaroscopy with USB digital microscopy in connective tissue diseases: a comparative study of 245 patients and healthy controls. Front Med (Lausanne). 2021;8:683900. doi:10.3389/fmed.2021.683900
   Web of Science ®Google Scholar
• Rattanakaemakorn P, Pinyowiwat P, Iamsumang W, Chanprapaph K, Suchonwanit P. Incidence and risk factors of hepatic fibrosis in psoriatic patients receiving methotrexate with concomitant acitretin therapy and methotrexate monotherapy. Drug Des Devel Ther. 2021;15:2299–2307. doi:10.2147/DDDT.S304168
   Web of Science ®Google Scholar